Haemonetics Corporation (HAE) — Fair Value Analysis

Base-case fair value (P50): $108.01 · Current price: $90.80 · Verdict: Undervalued

The Verdict on HAE

Based on our proprietary Monte Carlo simulations, HAEMONETICS CORP (HAE) is currently Fairly Valued. Our in-depth analysis indicates a median fair value (P50) of $108.01, suggesting a potential +19.0% upside from its current trading price of $90.80. This fair value assessment is derived from thousands of forward-looking scenarios, meticulously reflecting HAE's operational and financial health. The probabilistic outlook suggests that HAE is not significantly undervalued or overvalued at its current level. While our simulations point to a positive directional move towards the median target, investors should recognize that the current price of $90.80 already aligns reasonably with this comprehensive probabilistic assessment.

How HAE stacks up against peers

HAE's operational and financial health is assessed as "average" when compared against relevant sector norms. This quality tier assessment is a crucial input to our Monte Carlo simulations, influencing the range and probability of potential future outcomes across various scenarios. An average quality tier for HAE suggests a balanced risk profile relative to its industry peers, indicating that while it possesses strengths, it also carries typical industry challenges. While the median fair value of $108.01 still implies an +19.0% gap from $90.80, this average quality tier means the market's current valuation of $90.80 is largely reflective of its fundamental strengths and weaknesses within its competitive landscape, without the significant discounts or premiums often associated with extreme quality ratings.

What this means for investors

For investors tracking HAEMONETICS CORP (HAE), the "Fairly Valued" verdict signals that the stock, at $90.80, offers a balanced risk-reward profile leading to a median fair value of $108.01. The +19.0% potential towards this P50 target is derived from our rigorous Monte Carlo analysis, which models a wide array of market and company-specific variables to project future performance. Given HAE's average quality tier, the current valuation provides a reasonable entry point for those seeking exposure without significant speculative premiums or deep value discounts. To gain deeper insight into the full probability distribution, including detailed bear-case and bull-case scenarios for HAE, sign up for a free FairCurve account.